Importantly, IL-22 treatment downregulated expression of key genes involved in disease pathways including endocrine pancreatic dysfunction, Diabetes mellitus, severe pancreatic disorders, and impaired glucose tolerance (Supplementary Fig. 2c). Here, IL22 is linked to diabetes mellitus.